Ensartinib for Advanced ALK Rearranged Non-small Cell Lung Cancer

1 Views
administrator
administrator
07/14/23

UW Carbone Cancer Center physician Ticiana Leal, MD, explains this phase II study of X-396, now called ensartinib, a novel potent ALK inhibitor in patients with advanced ALK rearranged non-small cell lung cancer.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next